Citadel Advisors
ATYR

Citadel Advisors’s aTyr Pharma ATYR Stock Holding History

Citadel Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1K Buy
57,200
+9,400
+20% +$6.14K ﹤0.01% 13272
2026
Q1 		$37.3K Sell
47,800
-206,000
-81% -$174K ﹤0.01% 12518
2025
Q4 		$199K Sell
253,800
-385,400
-60% -$316K ﹤0.01% 11052
2025
Q3 		$461K Buy
639,200
+486,300
+318% +$2.2M ﹤0.01% 9335
2025
Q2 		$775K Buy
152,900
+41,100
+37% +$162K ﹤0.01% 7639
2025
Q1 		$338K Buy
111,800
+95,700
+594% +$349K ﹤0.01% 9317
2024
Q4 		$58.3K Buy
16,100
+13,000
+419% +$39.4K ﹤0.01% 12218
2024
Q3 		$5.46K Sell
3,100
-1,500
-33% -$2.73K ﹤0.01% 13486
2024
Q2 		$7.18K Buy
4,600
+1,400
+44% +$2.44K ﹤0.01% 13272
2024
Q1 		$6.24K Buy
3,200
+2,700
+540% +$4.71K ﹤0.01% 13694
2023
Q4 		$705 Sell
500
-3,000
-86% -$3.85K ﹤0.01% 13960
2023
Q3 		$5.53K Sell
3,500
-10,000
-74% -$18.5K ﹤0.01% 13386
2023
Q2 		$29.2K Buy
13,500
+10,300
+322% +$22.5K ﹤0.01% 12383
2023
Q1 		$6.72K Buy
3,200
+1,200
+60% +$2.63K ﹤0.01% 13784
2022
Q4 		$4.38K Buy
+2,000
New +$4.71K ﹤0.01% 14104
2022
Q3 		– Sell
-27,100
Closed -$77K – 13772
2022
Q2 		$77K Sell
27,100
-13,200
-33% -$47.7K ﹤0.01% 11630
2022
Q1 		$216K Buy
40,300
+5,500
+16% +$31.2K ﹤0.01% 11342
2021
Q4 		$260K Sell
34,800
-177,100
-84% -$1.48M ﹤0.01% 11254
2021
Q3 		$1.92M Buy
+211,900
New +$1.27M ﹤0.01% 6459

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's ATYR Position: Q2 2026 in Review

Citadel Advisors increased its aTyr Pharma (ATYR) stake by 2,522% in Q2 2026, buying an estimated $780K and bringing the position to 1,242,067 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #8927.

Citadel Advisors first reported a position in ATYR in Q4 2015 and has held it in 26 quarters since. The position peaked at $3.71M in Q1 2024. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Citadel Advisors held 1,242,067 shares of aTyr Pharma worth $741K as of Q2 2026.
  • Citadel Advisors bought 1,194,695 aTyr Pharma shares in Q2 2026, an estimated $780K.
  • aTyr Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8927 holding.
  • Citadel Advisors first reported a position in aTyr Pharma in Q4 2015 and has held it in 26 quarters since.
  • Citadel Advisors's aTyr Pharma position peaked at $3.71M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.